In addition, a randomized Phase II clinical trial is ongoing, using anti-IL-8 therapy compared to the standard of care in severe COVID-19 patients (ClinicalTrials.gov Identifier: NCT04347226 accessed on 30 November 2021). Here, CXCL8 is linked to COVID-19.